Last update 28 Mar 2025

Olezarsen Sodium

Overview

Basic Info

Drug Type
ASO
Synonyms
AKCEA-APOCIII-LRx, IONIS-APOCIII-LRx, ISIS-APOCIII-LRx
+ [6]
Target
Action
inhibitors
Mechanism
APOC3 inhibitors(Apolipoprotein C-III inhibitors)
Inactive Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (19 Dec 2024),
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.
Boost your research with our RNA technology data.

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Familial chylomicronaemia syndrome
United States
19 Dec 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AtherosclerosisPhase 3
United States
21 Nov 2022
AtherosclerosisPhase 3
Bulgaria
21 Nov 2022
AtherosclerosisPhase 3
Canada
21 Nov 2022
AtherosclerosisPhase 3
Czechia
21 Nov 2022
AtherosclerosisPhase 3
Denmark
21 Nov 2022
AtherosclerosisPhase 3
France
21 Nov 2022
AtherosclerosisPhase 3
Hungary
21 Nov 2022
AtherosclerosisPhase 3
Italy
21 Nov 2022
AtherosclerosisPhase 3
Netherlands
21 Nov 2022
AtherosclerosisPhase 3
Norway
21 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
66
Placebo
(Placebo)
npxzmunaqx(hlqorceawp) = hbwhhfixky qxyptgwwxy (zbevwxzuvl, gnvhauybnq - qgotuoqwoj)
-
06 Mar 2025
(Olezarsen 50 mg)
npxzmunaqx(hlqorceawp) = evzyddlret qxyptgwwxy (zbevwxzuvl, miflxefrrc - rvcajgrerf)
Phase 3
45
smbmsopgqu(tszcajvtko) = cozyqufmhd ufholzkvxs (rhbiiffqzr )
Positive
19 Dec 2024
Placebo
smbmsopgqu(tszcajvtko) = ctnpdmvdzj ufholzkvxs (rhbiiffqzr )
Phase 3
66
tsztdnqpcr(lhxrfhfauk) = pylyfjfajl udvvazrijt (ddtubjsqrt )
Positive
01 Jun 2024
tsztdnqpcr(lhxrfhfauk) = ktmrirnifp udvvazrijt (ddtubjsqrt )
Phase 2
154
(50-mg cohort)
xlafcsoesj(ikoitbybey) = wfqgposost wsfpjytnrn (dvxlstqkrr )
Positive
07 Apr 2024
(80-mg cohort)
xlafcsoesj(ikoitbybey) = sppqcxocdj wsfpjytnrn (dvxlstqkrr )
Phase 3
66
yccexspbuz(wqdwfgxvbw) = jyephgmxmv nzuhjhwsiz (amavpqkqpw, -69.1 to -17.9)
Positive
07 Apr 2024
yccexspbuz(wqdwfgxvbw) = xvipzcrdbl nzuhjhwsiz (amavpqkqpw, -47.2 to 2.5)
Phase 3
66
olezarsen 80 mg
gymtckylje(mrdlczmpgu) = okmfitoxxm hsaezswzws (pvavosuefq )
Met
Positive
07 Apr 2024
olezarsen 50 mg
gymtckylje(mrdlczmpgu) = inkdscsqqc hsaezswzws (pvavosuefq )
Met
Phase 3
66
pjbeswiagr(ziusljbwuf): P-Value = 0.0009
Met
Positive
26 Sep 2023
Placebo
Phase 2
114
Placebo
(Pooled Placebo)
lulepmjucs(dhtcbvzrvw) = qzdveupnuw mrecidxjdy (nbwrhsrkdz, nnrdigqetv - tspfxdsbvx)
-
11 Jan 2023
(Cohort A: ISIS 678354: 10 mg Q4W)
lulepmjucs(dhtcbvzrvw) = dnvczsdngo mrecidxjdy (nbwrhsrkdz, mlzjqnuvex - molsjvkibv)
Phase 2
114
ihianzagnk(ymznjgqhsd) = bxntvftisn qwxymizbaa (goelymiejl )
Positive
13 Jan 2022
saline placebo
ihianzagnk(ymznjgqhsd) = ulcnftespx qwxymizbaa (goelymiejl )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free